Dalia Wajsbrot

1.7k total citations · 1 hit paper
50 papers, 1.2k citations indexed

About

Dalia Wajsbrot is a scholar working on Urology, Pharmacology and Physiology. According to data from OpenAlex, Dalia Wajsbrot has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Urology, 12 papers in Pharmacology and 9 papers in Physiology. Recurrent topics in Dalia Wajsbrot's work include Hair Growth and Disorders (14 papers), Treatment of Major Depression (10 papers) and Autoimmune Bullous Skin Diseases (6 papers). Dalia Wajsbrot is often cited by papers focused on Hair Growth and Disorders (14 papers), Treatment of Major Depression (10 papers) and Autoimmune Bullous Skin Diseases (6 papers). Dalia Wajsbrot collaborates with scholars based in United States, Canada and Australia. Dalia Wajsbrot's co-authors include Eduardo Weltman, João Víctor Salvajoli, Reynaldo André Brandt, Rodrigo de Morais Hanriot, Flávio Eduardo Prisco, José C. Cruz, Ian Gilron, Jacinthe Lemay, Samuel H. Zwillich and Robert Wołk and has published in prestigious journals such as The Lancet, Circulation and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Dalia Wajsbrot

43 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

2023 134 citations Brett King, Xingqi Zhang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dalia Wajsbrot United States	18	367	316	248	220	212	50	1.2k
Seyed Behzad Jazayeri United States	15	192 0.5×	145 0.5×	107 0.4×	37 0.2×	91 0.4×	67	1.2k
Bo He China	17	158 0.4×	270 0.9×	75 0.3×	72 0.3×	19 0.1×	61	1.2k
Raj Tummala United States	25	70 0.2×	507 1.6×	108 0.4×	180 0.8×	118 0.6×	79	2.8k
Ryan P. Lee United States	14	55 0.1×	136 0.4×	123 0.5×	78 0.4×	117 0.6×	45	1.1k
Mustafa Kadıhasanoğlu Türkiye	15	309 0.8×	249 0.8×	92 0.4×	36 0.2×	40 0.2×	53	1.1k
Daniel B. Smith United States	18	73 0.2×	98 0.3×	185 0.7×	100 0.5×	81 0.4×	39	1.7k
Matthew Dixon United States	14	138 0.4×	393 1.2×	78 0.3×	152 0.7×	24 0.1×	26	1.4k
Chang‐Hsun Hsieh Taiwan	20	54 0.1×	84 0.3×	258 1.0×	31 0.1×	98 0.5×	69	1.2k
James Lee United States	19	365 1.0×	140 0.4×	129 0.5×	27 0.1×	25 0.1×	55	1.1k
Piotr Radziszewski Poland	22	261 0.7×	141 0.4×	673 2.7×	68 0.3×	20 0.1×	137	2.6k

Countries citing papers authored by Dalia Wajsbrot

Since Specialization

Citations

This map shows the geographic impact of Dalia Wajsbrot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dalia Wajsbrot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dalia Wajsbrot more than expected).

Fields of papers citing papers by Dalia Wajsbrot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dalia Wajsbrot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dalia Wajsbrot. The network helps show where Dalia Wajsbrot may publish in the future.

Co-authorship network of co-authors of Dalia Wajsbrot

This figure shows the co-authorship network connecting the top 25 collaborators of Dalia Wajsbrot. A scholar is included among the top collaborators of Dalia Wajsbrot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dalia Wajsbrot. Dalia Wajsbrot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Senna, Maryanne M., Ignasi Figueras‐Nart, Misaki Kinoshita‐Ise, et al.. (2025). Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study. SKIN The Journal of Cutaneous Medicine. 9(4). s582–s582.

King, Brett, Xingqi Zhang, Jacek C. Szepietowski, et al.. (2023). A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata. Immunotherapy. 15(14). 1093–1103. 4 indexed citations

King, Brett, Paradi Mirmirani, Kristen Lo Sicco, et al.. (2023). 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies. Journal of Investigative Dermatology. 143(11). S344–S344. 2 indexed citations

King, Brett, Paradi Mirmirani, Kristen Lo Sicco, et al.. (2023). LB1697 Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study. Journal of Investigative Dermatology. 143(9). B15–B15. 2 indexed citations

Zilcha‐Mano, Sigal, et al.. (2021). Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials. Journal of Clinical Psychopharmacology. 41(5). 579–584.

Kato, Masaki, Yuko Asami, Dalia Wajsbrot, et al.. (2020). Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. Journal of Psychiatric Research. 129. 160–167. 6 indexed citations

Katzman, Martin A., et al.. (2020). Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. Journal of Psychopharmacology. 34(3). 280–292. 9 indexed citations

Prieto, Rita, et al.. (2019). Efficacy of venlafaxine extended release in major depressive disorder patients. International Clinical Psychopharmacology. 34(3). 110–118. 17 indexed citations

Soares, Cláudio N., Dalia Wajsbrot, & Matthieu Boucher. (2019). Predictors of functional response and remission with desvenlafaxine 50 mg and 100 mg: a pooled analysis of randomized, placebo-controlled studies in patients with major depressive disorder. CNS Spectrums. 25(3). 363–371. 1 indexed citations

10.

Bradley, John S., Helen Broadhurst, Karen Cheng, et al.. (2019). Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial. The Pediatric Infectious Disease Journal. 38(8). 816–824. 49 indexed citations

11.

Atkinson, Sarah, et al.. (2018). Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials. CNS Spectrums. 24(5). 496–506. 7 indexed citations

12.

Wigal, Sharon B., Ann Childress, Susan A. Berry, et al.. (2018). Optimization of Methylphenidate Extended-Release Chewable Tablet Dose in Children with ADHD: Open-Label Dose Optimization in a Laboratory Classroom Study. Journal of Child and Adolescent Psychopharmacology. 28(5). 314–321. 9 indexed citations

13.

Atkinson, Sarah, Shannon L. Lubaczewski, Richard D. England, et al.. (2017). Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology. 28(1). 55–65. 23 indexed citations

14.

Katzman, Martin A., Andrew A. Nierenberg, Dalia Wajsbrot, et al.. (2017). Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. 37(5). 555–561. 5 indexed citations

15.

Weihs, Karen L., et al.. (2017). Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder. Journal of Child and Adolescent Psychopharmacology. 28(1). 36–46. 26 indexed citations

16.

Lam, Raymond W., Dalia Wajsbrot, Ellen Meier, et al.. (2017). Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. Journal of Psychopharmacology. 31(9). 1204–1214. 6 indexed citations

17.

Thase, Michael E., Yuko Asami, Dalia Wajsbrot, et al.. (2016). A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder. Current Medical Research and Opinion. 33(2). 317–326. 9 indexed citations

18.

Distiller, Larry A., et al.. (2014). An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa. Journal of International Medical Research. 42(4). 1018–1028. 27 indexed citations

19.

Furtado, Juvêncio José Duailibe, José Valdez Madruga, Max Igor Banks Ferreira Lopes, et al.. (2013). Safety and Immunovirologic Outcomes with Maraviroc Combination Regimens in Patients with a History of Past Treatment Failures and Virologic Resistance in Brazil: An Open-Label, Multicenter Phase 3b Study. AIDS Research and Human Retroviruses. 29(9). 1203–1210. 5 indexed citations

20.

González, Juan Carlos Acevedo, et al.. (2010). A prospective, open-label, multicentre study of pregabalin in the treatment of neuropathic pain in Latin America. International Journal of Clinical Practice. 64(9). 1301–1309. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact